Griffin Asset Management Inc. Has $2.62 Million Position in Pulse Biosciences, Inc. (NASDAQ:PLSE)

Griffin Asset Management Inc. increased its holdings in shares of Pulse Biosciences, Inc. (NASDAQ:PLSE) by 15.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 300,320 shares of the company’s stock after purchasing an additional 40,700 shares during the period. Griffin Asset Management Inc. owned approximately 0.54% of Pulse Biosciences worth $2,616,000 at the end of the most recent quarter.

Separately, PNC Financial Services Group Inc. acquired a new position in shares of Pulse Biosciences in the fourth quarter valued at approximately $242,000. 76.95% of the stock is owned by institutional investors.

Pulse Biosciences Stock Up 1.6 %

Pulse Biosciences stock traded up $0.18 during midday trading on Friday, reaching $11.19. The stock had a trading volume of 879,733 shares, compared to its average volume of 219,934. The firm’s fifty day simple moving average is $10.06 and its 200-day simple moving average is $9.55. Pulse Biosciences, Inc. has a 1-year low of $3.78 and a 1-year high of $14.96.

Pulse Biosciences (NASDAQ:PLSE) last announced its earnings results on Tuesday, May 7th. The company reported ($0.17) EPS for the quarter.

Wall Street Analyst Weigh In

Separately, StockNews.com raised shares of Pulse Biosciences to a “sell” rating in a research note on Thursday.

Insider Transactions at Pulse Biosciences

In related news, CEO Burke Thomas Barrett purchased 10,000 shares of the firm’s stock in a transaction on Monday, May 20th. The stock was purchased at an average cost of $8.56 per share, for a total transaction of $85,600.00. Following the completion of the purchase, the chief executive officer now directly owns 10,000 shares in the company, valued at $85,600. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 71.50% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.